Mirtazapine for the treatment of hot flushes in breast cancer survivors: A prospective pilot trial

Breast Journal

Volumn 13, Issue 5, 2007, Pages 490-495

  Biglia, Nicoletta ^a,b   Kubatzki, Franziska ^a   Sgandurra, Paola ^a   Ponzone, Riccardo ^a   Marenco, Davide ^a   Peano, Elisa ^a   Sismondi, Piero ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

Author keywords

Breast cancer survivors; Hot flushes; Menopausal symptoms; Mirtazapine

Indexed keywords

ANTIDEPRESSANT AGENT; MIRTAZAPINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEALTH SURVEY; HOT FLUSH; HUMAN; MENOPAUSAL SYNDROME; PATIENT COMPLIANCE; SIDE EFFECT; SLEEP PATTERN; SOMNOLENCE; WEIGHT GAIN;

ADULT; AGED; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; HOT FLASHES; HUMANS; MIANSERIN; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVORS;

EID: 34548286794     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2007.00470.x     Document Type: Article

References (24)

1. Ganz P. Menopause and breast cancer: symptoms, late effects, and their management. Semin Oncol 2001 28 : 274 83.
2. Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003 45 : 29 38.
3. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 2004 11 : 11 13.
4. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet 2004 363 : 453 55.
5. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994 331 : 347 52.
6. Bertelli G, Venturini M, Del Mastro L, et al. Intramuscolar depot- medroxiprogesterone versus oral megestrol for the control of postmenopausal hot flushes in breast cancer patients: a randomized study. Ann Oncol 2002 13 : 883 88.
7. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998 16 : 495 500.
8. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flushes in breast cancer survivors: North Central Cancer Treatment Group Trial. J Clin Oncol 2000 18 : 1068 74.
9. Chen Y, Lu X, Huang Y, Xin X, Ye X. Changes of plasma serotonin precursor metabolite concentrations in postmenopausal women with hot flushes. Zhonghua Fu Chan Ke Za Zhi 2002 37 : 726 28.
10. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flushes in survivors of breast cancer: a randomised controlled trial. Lancet 2000 356 : 2059 63.
11. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III Evaluation of Fluoxetine for treatment of hot flushes. J Clin Oncol 2002 20 : 1578 83.
12. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA, 2003 289 : 2827 34.
13. Berendsen HH The role of serotonin in hot flushes. Maturitas 2000 31, 36 : 155 64.
14. Waldinger MD, Berendsen HH, Schweitzer DH Treatment of hot flushes with miratzapine: four case reports. Maturitas 2000 31, 36 : 165 68.
15. Perez DG, Loprinzi CL, Barton DL, et al. Pilot evaluation of Mirtazapine for the treatment of hot flushes. J Support Oncol 2004 2 : 50 56.
16. Sloan JA, Loprinzi Cl, Novonty PJ, Barton DL, Lavasseur BI, Windshitl H. Methodologic lessons learned from hot flushes studies. J Clin Oncol 2001 19 : 4280 90.
17. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989 28 : 193 213.
18. Heinemann K, Ruebig A, Potthoff P, et al. The Menopause Rating Scale (MRS): a methodological review. Health Qual Life Outcomes 2004 2 : 45.
19. Ware J Jr., Snow K, Konsinski M, Gandek B. SF-36 Health Survey. Manual and Interpretation Guide. Boston : The Health Institute, New England Medical Center, 1993.
20. Day R, Ganz PA, Costantino JO. Health-related quality of life and Tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast an Bowel Project P-1 study. J Clin Oncol 1999 17 : 2659 69.
21. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flushes. Fertil Steril 1998 70 : 71 76.
22. Nutt DJ. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol 2002 17 (Suppl S37 41.
23. Stearns V, Johnson MD, Rae JM, et al. Active Tamoxifen metabolite plasma concentrations after coadministration of Tamoxifen and SSRI paroxetine. J Natl Cancer Inst 2003 95 : 1758 64.
24. Goetz MP, Loprinzi CL. A hot flash on tamoxifen metabolism. J Natl Cancer Inst 2003 95 : 1734 35.